# Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: PRLD
Company: Prelude Therapeutics
Source: Prelude Therapeutics
Published: 2026-05-12 11:01 EST
Original Source URL: https://investors.preludetx.com
## Summary

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in

## Article Body
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in
## Recent Company News
- 2026-05-12 11:01 EST — [Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Prelude Therapeutics
- 2026-04-20 10:30 EST — [Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering) — Source: Prelude Therapeutics
- 2026-04-20 10:00 EST — [Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly-selective-kat6a-degrader-at-american-association-for-cancer-research-aacr-annual-meeting-2026) — Source: Prelude Therapeutics
- 2026-04-15 11:30 EST — [Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-the-appointment-of-charles-morris-m-d-as-chief-medical-officer) — Source: Prelude Therapeutics
- 2026-03-17 20:31 EST — [Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PRLD/prelude-therapeutics-announces-acceptance-of-preclinical-abstract-for-prt13722-a-first-in-class-oral-kat6a-selective-degrader-at-the-2026-aacr-annual-meeting) — Source: Prelude Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)